An interventional study of SynergEyes Hybrid (petrafocon A hem-larafilcon A) Hybrid Contact Lens and SynergEyes Hybrid (paflufocon D hem-iberfilcon A) Contact Lens in Corneal Disease and Hypersensitivity, sponsored by SynergEyes, Inc.. Completed at 8 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2009-12-23.
Sponsored by SynergEyes, Inc. · Not applicable, Interventional, and Treatment
The purpose of the study is to demonstrate that the SynergEyes SA Hybrid Contact Lens clinical performance is substantially equivalent to that of the SynergEyes A Hybrid Lens when studied:
The objective of the study is to compare the SynergEyes SA Hybrid Contact Lens (Test) to the SynergEyes A Hybrid Contact lens (Control) when used in a daily wear regimen on non-diseased eyes for the correction of myopia (-0.25 to -6.00Diopters) with up to -2.50 Diopters of astigmatism. The population will be randomized into a 2/1 ratio of the Test/Control for 90 days. The study objective is to complete at least 40 subjects in the Test material and 20 subjects in the Control material.
The purpose of the study is to demonstrate that the SynergEyes SA Hybrid Contact Lens clinical performance is substantially equivalent to that of the SynergEyes A Hybrid Lens when studied within the corresponding range of powers in a population randomized within investigational sites to produce a 2/1 ratio of Test vs. Control lenses.
130 studies on the registry are indexed under Corneal Diseases; 43 are open to participants now.
This study's enrollment of 98 is above the median of 32 across 78 interventional studies indexed under Corneal Diseases.
Browse Corneal Diseases studies →SynergEyes, Inc. is the lead sponsor of 2 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Prior to being considered eligible to participate in this study, each subject MUST:
Have
Exclusion Criteria:
Subjects may not be enrolled into the study if ANY of the following apply:
Slit lamp findings that would contraindicate contact lens wear, including but not limited to:
TO BE ELIGIBLE TO BE RANDOMIZED FOR STUDY PRODUCT TRIAL A SUBJECT MUST HAVE ALL OF THE INCLUSION CRITERIA AND NONE OF THE EXCLUSION CRITERIA PRESENT.
TO BE ELIGIBLE FOR LENS DISPENSING, THE SUBJECT'S STUDY DEVICE CONTACT LENS VISUAL ACUITY MUST BE EQUAL TO OR BETTER THAN 20/30 IN EACH EYE
Test arm daily wear hybrid contact lens.
Device: SynergEyes Hybrid (petrafocon A hem-larafilcon A) Hybrid Contact Lens
Control: SynergEyes Hybrid (paflufocon D hem-iberfilcon A) Hybrid Contact Lens
Device: SynergEyes Hybrid (paflufocon D hem-iberfilcon A) Contact Lens
Comparison to control hybrid lens with similar 'dose'minimum 8 hours daily use for up to 90 days.
Comparison to test lens: Daily use for minimum 8 hours up to 90 days.
Comparison of objective findings (slit lamp, lens fitting, deposits, subjective symptoms, adverse events test vs control
Time frame: 3 months
Visual acuity comparison test/control.
Time frame: 3 mo.
This study is completed, as verified in Dec 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
SynergEyes, Inc.